Cognetivity Sees Its Cognitive Tool Used In Clinical Study For OCD
While it may have been initially developed for the early detection of Alzheimer’s disease or other cognitive impairments in patients,
Read moreWhile it may have been initially developed for the early detection of Alzheimer’s disease or other cognitive impairments in patients,
Read moreCognetivity Neurosciences (CSE: CGN) appears to be on a roll when it comes to establishing pilot programs in new markets.
Read moreCognetivity Neurosciences (CSE: CGN) continues to expand upon its global reach, this morning announcing its first step into the Asian
Read moreJoining us again on The Daily Dive is Dr. Thomas Sawyer, COO of Cognetivity Neurosciences (CSE: CGN). Today, Tom sits
Read moreA successful pilot program has lead to a commercial arrangement for Cognetivity Neurosciences (CSE: CGN). The firm this morning revealed
Read moreCognetivity Neurosciences (CSE: CGN) continued to take the Middle East by storm this morning. The firm has continued its pattern
Read moreThe rollout of Cognetivity Neurosciences’ (CSE: CGN) flagship product, the CognICA cognitive assessment tool, continues. The firm this morning announced
Read moreCognetivity Neuroscience (CSE: CGN) is looking to expand the scope of its cognitive testing platform. The company this morning announced
Read moreCognetivity Neurosciences (CSE: CGN) continues to expand its footprint within the Middle East. This morning, the company indicated that it
Read moreCognetivity Neurosciences (CSE: CGN) continues to expand the deployment of its Integrated Cognitive Assessment, or ICA. The firm this morning
Read more